Skip to the briefing Turn a clinic search into questions QUESTION KIT / CHECK THE STATUS Take the question at your own pace. Does the approval claim hold up? Someone says the rules changed. Before accepting that answer, ask which rule changed and where the change is recorded. Approval, medicine made to order by a pharmacy, and a request later taken back are different things. Ask about the exact product CHECK / OPEN The approval claim The exact substance The rule being cited The dated record Follow the claim to the final record. There is no approved use By September 2026, no use of BPC-157 had FDA approval in the United States. FDA's review also says it found no approved medicine containing BPC-157 in any country. Compounding means preparing a medicine to order. A doctor or pharmacist makes it for a patient in place of a ready-made product from a drug company. Compounded medicines lacked FDA approval as of September 2026; FDA also did not check their safety, quality and effect before marketing. Ask the person offering the product to identify its status clearly. A broad answer about peptides does not answer that question. Ask during the conversation Would I receive an approved medicine or a medicine prepared to order? Which US government rule lets the pharmacy make this medicine for me? Please show me the rule and explain how this ingredient meets it. A withdrawn request does not grant permission FDA lists BPC-157 under requests that were taken back, on the page checked in September 2026. The page is marked current April 22, 2026. It does not say when the requests were taken back. The groups seeking pharmacy use took their requests back; that is not FDA clearance of BPC-157. BPC-157 does not meet the federal rules for raw ingredients used by ordinary pharmacies to make medicine to order, based on FDA records checked in September 2026. First, an ingredient must meet the written quality standard in the recognised medicine standards books, if one exists. This means rules for what the ingredient must contain and how it is checked. Without such a standard, it must be an ingredient in an FDA-approved medicine. If neither route applies, the ingredient must appear on FDA's list of extra ingredients pharmacies may use. Ask for the exact rule and the date of the record being cited. Keep a copy of the answer. Ask during the conversation Does the record show permission, or only a request that was withdrawn? A committee discussion is advice FDA staff proposed excluding BPC-157 from the list of extra ingredients that ordinary pharmacies can use for medicines made to order. That proposal was made in July 2026. By September 28, 2026, the FDA had not posted an official record showing how the advisory committee voted. A committee vote is advice and cannot change the permitted list. FDA must publish its proposed rule, invite comments from the public and publish the final rule before the list can change. Ask to see that final rule and its date when someone says the law has changed. Ask them to show where it allows the ingredient they would use. Ask during the conversation Can you show the final rule rather than a report about the meeting? Source notes for this briefing FDA's tables and the concerns beside them FDA staff's assessment The meeting documents FDA has posted FDA's ingredient-list process Start Check the status Previous: Understand the offer Next: Check a licence The guide helps you ask care questions; this site runs no clinic and supplies no product. Find a briefing Question sheet Read this briefing as text Take the next question when you are ready.